{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-24-000205","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2024-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.339420+00:00","generated_at":"2026-05-30T16:43:52.017269+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Denali partner Sanofi discontinues K2 Phase 2 study of oditrasertib in MS after missing endpoints","bullets":["Sanofi discontinued K2 Phase 2 study of oditrasertib (SAR443820/DNL788) in multiple sclerosis.","Study did not meet primary and key secondary endpoints based on serum neurofilament light chain levels.","Denali was informed by partner Sanofi; no further details on safety or next steps provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-24-000205","json":"https://secwatch.observer/filing/0001714899-24-000205.json","markdown":"https://secwatch.observer/filing/0001714899-24-000205.md","text":"https://secwatch.observer/filing/0001714899-24-000205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000205/0001714899-24-000205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000205/dnli-20241010.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T16:43:52.017269+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}